Cargando…

Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs

BACKGROUND: Cardiac wall stress and high oxidative stress are often found in cases of myxomatous mitral valve degenerative (MMVD) disease and can lead to myocardial injuries and cardiac dysfunction. Melatonin, an antioxidant, has been shown to exert cardioprotection in laboratory animal models. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pongkan, Wanpitak, Piamsiri, Chanon, Dechvongya, Sirada, Punyapornwitthaya, Verasak, Boonyapakorn, Chavalit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740462/
https://www.ncbi.nlm.nih.gov/pubmed/34996468
http://dx.doi.org/10.1186/s12917-021-03125-z
_version_ 1784629318164414464
author Pongkan, Wanpitak
Piamsiri, Chanon
Dechvongya, Sirada
Punyapornwitthaya, Verasak
Boonyapakorn, Chavalit
author_facet Pongkan, Wanpitak
Piamsiri, Chanon
Dechvongya, Sirada
Punyapornwitthaya, Verasak
Boonyapakorn, Chavalit
author_sort Pongkan, Wanpitak
collection PubMed
description BACKGROUND: Cardiac wall stress and high oxidative stress are often found in cases of myxomatous mitral valve degenerative (MMVD) disease and can lead to myocardial injuries and cardiac dysfunction. Melatonin, an antioxidant, has been shown to exert cardioprotection in laboratory animal models. However, its effect on metabolic parameters and left ventricular (LV) adaptation in MMVD dogs has rarely been investigated. This clinical trial hypothesized that a melatonin supplement for 4 weeks would improve metabolic parameters, LV structure (diameters and wall thickness), and LV function in MMVD dogs. Blood profiles, echocardiograms, and oxidative stress levels were obtained from 18 dogs with MMVD stage B2 and C at baseline and after prescribed Melatonin (2 mg/kg) for 4 weeks. Eleven dogs with MMVD stage B2 and C, which received a placebo, were evaluated as a control group. RESULTS: In this clinical trial, the baseline plasma malondialdehyde (MDA) was no different between the treatment and placebo groups. The post-treatment plasma MDA levels (4.50 ± 0.63 mg/mL) in the treatment group was significantly decreased after 4 weeks of melatonin supplementation compared to pre-treatment levels (7.51 ± 1.11 mg/mL) (P = 0.038). However, blood profiles and LV structure and function investigated using echocardiography were found not to different between pre-and post-treatment in each group. No adverse effects were observed following melatonin supplementation. CONCLUSIONS: This clinical trial demonstrated that a melatonin supplement for 4 weeks can attenuate oxidative stress levels in MMVD dogs, especially in MMVD stage C, but does not result in LV structural changes or LV function in MMVD dogs of either stage B2 or stage C.
format Online
Article
Text
id pubmed-8740462
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87404622022-01-07 Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs Pongkan, Wanpitak Piamsiri, Chanon Dechvongya, Sirada Punyapornwitthaya, Verasak Boonyapakorn, Chavalit BMC Vet Res Research BACKGROUND: Cardiac wall stress and high oxidative stress are often found in cases of myxomatous mitral valve degenerative (MMVD) disease and can lead to myocardial injuries and cardiac dysfunction. Melatonin, an antioxidant, has been shown to exert cardioprotection in laboratory animal models. However, its effect on metabolic parameters and left ventricular (LV) adaptation in MMVD dogs has rarely been investigated. This clinical trial hypothesized that a melatonin supplement for 4 weeks would improve metabolic parameters, LV structure (diameters and wall thickness), and LV function in MMVD dogs. Blood profiles, echocardiograms, and oxidative stress levels were obtained from 18 dogs with MMVD stage B2 and C at baseline and after prescribed Melatonin (2 mg/kg) for 4 weeks. Eleven dogs with MMVD stage B2 and C, which received a placebo, were evaluated as a control group. RESULTS: In this clinical trial, the baseline plasma malondialdehyde (MDA) was no different between the treatment and placebo groups. The post-treatment plasma MDA levels (4.50 ± 0.63 mg/mL) in the treatment group was significantly decreased after 4 weeks of melatonin supplementation compared to pre-treatment levels (7.51 ± 1.11 mg/mL) (P = 0.038). However, blood profiles and LV structure and function investigated using echocardiography were found not to different between pre-and post-treatment in each group. No adverse effects were observed following melatonin supplementation. CONCLUSIONS: This clinical trial demonstrated that a melatonin supplement for 4 weeks can attenuate oxidative stress levels in MMVD dogs, especially in MMVD stage C, but does not result in LV structural changes or LV function in MMVD dogs of either stage B2 or stage C. BioMed Central 2022-01-07 /pmc/articles/PMC8740462/ /pubmed/34996468 http://dx.doi.org/10.1186/s12917-021-03125-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Pongkan, Wanpitak
Piamsiri, Chanon
Dechvongya, Sirada
Punyapornwitthaya, Verasak
Boonyapakorn, Chavalit
Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs
title Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs
title_full Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs
title_fullStr Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs
title_full_unstemmed Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs
title_short Short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs
title_sort short-term melatonin supplementation decreases oxidative stress but does not affect left ventricular structure and function in myxomatous mitral valve degenerative dogs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740462/
https://www.ncbi.nlm.nih.gov/pubmed/34996468
http://dx.doi.org/10.1186/s12917-021-03125-z
work_keys_str_mv AT pongkanwanpitak shorttermmelatoninsupplementationdecreasesoxidativestressbutdoesnotaffectleftventricularstructureandfunctioninmyxomatousmitralvalvedegenerativedogs
AT piamsirichanon shorttermmelatoninsupplementationdecreasesoxidativestressbutdoesnotaffectleftventricularstructureandfunctioninmyxomatousmitralvalvedegenerativedogs
AT dechvongyasirada shorttermmelatoninsupplementationdecreasesoxidativestressbutdoesnotaffectleftventricularstructureandfunctioninmyxomatousmitralvalvedegenerativedogs
AT punyapornwitthayaverasak shorttermmelatoninsupplementationdecreasesoxidativestressbutdoesnotaffectleftventricularstructureandfunctioninmyxomatousmitralvalvedegenerativedogs
AT boonyapakornchavalit shorttermmelatoninsupplementationdecreasesoxidativestressbutdoesnotaffectleftventricularstructureandfunctioninmyxomatousmitralvalvedegenerativedogs